Cardiovascular risk and adrenergic overdrive in the metabolic syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 6, 2007, Pages 473-481

  Grassi, Guido ^a,b,c   Quarti Trevano, Fosca ^a   Seravalle, Gino ^b   Dell'Oro, Raffaella ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Centro Interuniversitario   (Italy)

Author keywords

Central sympatholytic drugs; Insulin; Metabolic syndrome; Obesity; Sympathetic nervous system

Indexed keywords

CARDIOVASCULAR AGENT;

ADRENERGIC NERVE; ADRENERGIC SYSTEM; BLOOD PRESSURE; BLOOD VESSEL; CARDIOMEGALY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; INNERVATION; LIFESTYLE; METABOLIC SYNDROME X; METABOLISM; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ADRENERGIC FIBERS; BLOOD PRESSURE; BLOOD VESSELS; CARDIOMEGALY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 34447514179     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.01.004     Document Type: Review

References (57)

1. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
2. Howard W.J. The metabolic syndrome: is a critical appraisal really necessary? The point of view of a practicing physician. Nutr Metab Cardiovasc Dis 16 (2006) 85-87
3. Iribarren C., Go A.S., Husson G., Sidney S., Fair J.M., Quertermous T., et al. Metabolic syndrome and early-onset coronary artery disease. Is the whole greater than its parts?. J Am Coll Cardiol 48 (2006) 1800-1807
4. Mancia G., Bombelli M., Corrao G., Facchetti R., Madotto F., Grassi G., et al. The metabolic syndrome in the Pamela population: daily life blood pressure, cardiac damage and prognosis. Hypertension 49 (2007) 40-47
5. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
6. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15 (2005) 250-254
7. Alberti K.G., Zimmet P., Shaw J., and for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366 (2005) 1059-1062
8. Esposito K., and Giugliano D. The metabolic syndrome and inflammation: association or causation?. Nutr Metab Cardiovasc Dis 14 (2004) 228-232
9. Siani A., and Strazzullo P. Tackling the genetic bases of metabolic syndrome: a realistic objective?. Nutr Metab Cardiovasc Dis 16 (2006) 309-312
10. Ritchie S.A., and Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis (2006) [Epub ahead of print]
11. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 374-381
12. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61 (1986) 1081-1090
13. Goldstein D.S. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5 (1983) 86-99
14. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., and Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31 (1998) 68-72
15. Esler M., Lambert G., and Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens 11 (1989) 75-89
16. Ferrier C., Esler M.D., Eisenhofer G., Wallin B.G., Horne M., Cox H., et al. Increased norepinephrine spillover into the jugular veins in essential hypertension. Hypertension 19 (1992) 62-69
17. Mancia G., Grassi G., Giannattasio C., and Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34 (1999) 724-728
18. Grassi G., and Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution?. Hypertension 43 (2004) 154-155
19. Silva J.E. Thermogenic mechanisms and their hormonal regulation. Physiol Rev 86 (2006) 435-464
20. Frontoni S., Bracaglia D., and Gigli F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr Metab Cardiovasc Dis 15 (2005) 441-449
21. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 19 (2001) 1713-1716
22. Esler M., Straznicky N., Eikelis N., Masuo K., Lambert G., and Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48 (2006) 787-796
23. Grassi G., Vailati S., Bertinieri G., Seravalle G., Stella M.L., Dell'Oro R., et al. Heart rate as a marker of sympathetic overactivity. J Hypertens 16 (1998) 1635-1639
24. Young J.B., and Macdonald I.A. Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 16 (1992) 959-967
25. Grassi G., Seravalle G., Cattaneo B.M., Bolla G.B., Lanfranchi A., Colombo M., et al. Sympathetic activation in obese normotensive subjects. Hypertension 25 (1995) 560-563
26. Grassi G., Seravalle G., Dell'Oro R., Turri C., Bolla G.B., and Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36 (2000) 538-542
27. Grassi G., Dell'Oro R., Facchini A., Quarti Trevano F., Bolla G.B., and Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 22 (2004) 2363-2369
28. Wolk R., Shamsuzzaman A.S., and Somers V.K. Obesity, sleep apnea, and hypertension. Hypertension 42 (2003) 1067-1074
29. Grassi G., Facchini A., Quarti Trevano F., Dell'Oro R., Arenare F., Tana F., et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46 (2005) 321-325
30. Huggett R.J., Scott E.M., Gilbey S.G., Stoker J.B., Mackintosh A.F., and Mary D.A. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108 (2003) 3097-3101
31. Huggett R.J., Burns J., Mackintosh A.F., and Mary D. Sympathetic neural activation in non-diabetic metabolic syndrome and its further augmentation by hypertension. Circulation 44 (2004) 847-852
32. Grassi G., Dell' Oro R., Quarti Trevano F., Scopelliti F., Seravalle G., Paleari F., et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48 (2005) 1359-1365
33. Chinali M., Devereux R.B., Howard B.V., Roman M.J., Bella J.N., Liu J.E., et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome. Am J Cardiol 93 (2004) 40-44
34. De Simone G. State of the heart in the metabolic syndrome. Nutr Metab Cardiovasc Dis 15 (2005) 239-241
35. Devereux R.B., de Simone G., Palmieri V., Oberman A., Hopkins P., Kitzman D.W., et al. Relation of insulin left ventricular geometry and function in African American and white hypertensive adults: the HyperGEn study. Am J Hypertens 15 (2002) 1029-1035
36. Burchfiel C.M., Skelton T.N., Andrew M.E., Garrison R.J., Arnett D.K., Jones D.W., et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (AIRC) Study. Circulation 112 (2005) 819-827
37. Cuspidi C., Meani S., Fusi V., Severgnini B., Valerio C., Catini E., et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertension 22 (2004) 1991-1998
38. Grassi G. Sympathetic overdrive as an independent predictor of left ventricular hypertrophy: prospective evidence. J Hypertens 24 (2006) 815-817
39. Patel M.B., Stewart J.M., Loud A.V., Anversa P., Wang J., Fiegel L., et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 84 (1991) 2091-2100
40. Schlaich M.P., Kaye D.M., Lambert E., Sommerville M., Socratous F., and Esler M.D. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108 (2003) 560-565
41. Greenwood J.P., Scott E.M., Stoker J.B., and Mary D.A. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 38 (2001) 1711-1717
42. De Simone G., Pasanisi F., and Contaldo F. Link of non-hemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension 38 (2001) 13-18
43. De Simone G., Devereux R.B., Calmieri V., Roman M.J., Cementano A., Welty T.K., et al. Relation of insulin resistance to makers of preclinical cardiovascular disease: the Strong Heart Study. Nutr Metab Cardiovasc Dis 13 (2003) 140-147
44. Scuteri A., Najjar S.S., Muller D.C., Andres R., Hougaku H., Metter E.J., et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 43 (2004) 1388-1395
45. Mule G., Cottone S., Mongiovi R., Cusimano P., Mezzatesta G., Seddio G., et al. Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 16 (2006) 54-59
46. Bots M.L., Hoes A.W., Koundstaal P.J., Hofman A., and Gobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96 (1997) 1432-1437
47. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
48. De Backer G., Ambriosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of the European and other Societies on Cardiovascular Diseases Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
49. Pasanisi F., Contaldo F., de Simone G., and Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 11 (2001) 401-406
50. Gayda M., Brun C., Juneau M., Levesque S., and Nigam A. Long-term cardiac rehabilitation and exercise training programs improve metabolic parameters in metabolic syndrome patients with and without coronary heart disease. Nutr Metab Cardiovasc Dis (2006) Epub ahead of print
51. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
52. Grassi G., Seravalle G., Colombo M., Bolla G.B., Cattaneo B.M., Cavagnini F., et al. Body weight reduction, sympathetic nerve traffic and arterial baroreflex in obese normotensive humans. Circulation 97 (1998) 2037-2042
53. Straznicky N.E., Lambert E.A., Lambert G.W., Masuo K., Esler M.D., and Nestel P.J. Effects of dietary weight loss of sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 5998-6005
54. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24 (2006) 3-10
55. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 13 (2004) 513-519
56. Grassi G., Seravalle G., Dell'Oro R., Quarti Trevano F., Bombelli M., Scopelliti F., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 21 (2003) 1761-1769
57. Pessina A.C., Ciccariello L., Perrone F., Stoico V., Gussoni G., Scotti A., et al. Clinical efficacy and tolerability of alpha-blocker doxazozin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 16 (2006) 137-147